PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1536.00 - 1565.00
1090.00 - 1784.00
46.2K / 155.6K (Avg.)
23.48 | 66.41
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-4.09%
Negative revenue growth while 4997.T stands at 25.69%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
20.02%
Gross profit growth under 50% of 4997.T's 41.68%. Michael Burry would be concerned about a severe competitive disadvantage.
220.05%
EBIT growth below 50% of 4997.T's 1559.82%. Michael Burry would suspect deeper competitive or cost structure issues.
433.12%
Operating income growth under 50% of 4997.T's 1559.82%. Michael Burry would be concerned about deeper cost or sales issues.
584.80%
Net income growth at 50-75% of 4997.T's 971.68%. Martin Whitman would question fundamental disadvantages in expenses or demand.
586.19%
EPS growth at 50-75% of 4997.T's 1117.36%. Martin Whitman would suspect a lag in operational efficiency or a higher share count.
586.19%
Diluted EPS growth at 50-75% of 4997.T's 1117.36%. Martin Whitman would question if share issuance or modest net income gains hamper progress.
-0.00%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-0.00%
Reduced diluted shares while 4997.T is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
2.62%
OCF growth of 2.62% while 4997.T is zero. Bruce Berkowitz would see if small gains can expand into a larger competitive lead.
2.62%
FCF growth of 2.62% while 4997.T is zero. Bruce Berkowitz would see if modest improvements in free cash can accelerate further.
68.20%
10Y revenue/share CAGR under 50% of 4997.T's 148.11%. Michael Burry would suspect a lasting competitive disadvantage.
10.27%
5Y revenue/share CAGR under 50% of 4997.T's 28.51%. Michael Burry would suspect a significant competitive gap or product weakness.
2.58%
3Y revenue/share CAGR under 50% of 4997.T's 67.24%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
70.33%
Below 50% of 4997.T's 687.57%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
614.27%
5Y net income/share CAGR above 1.5x 4997.T's 244.35%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
-27.77%
Negative 3Y CAGR while 4997.T is 591.78%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
355.71%
10Y equity/share CAGR above 1.5x 4997.T's 64.29%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
41.84%
5Y equity/share CAGR above 1.5x 4997.T's 13.30%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
24.87%
3Y equity/share CAGR 1.25-1.5x 4997.T's 17.23%. Bruce Berkowitz confirms timely buybacks or margin improvements drive stronger near-term equity growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.00%
Firm’s AR is declining while 4997.T shows 17.73%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
10.48%
Inventory growth well above 4997.T's 8.62%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-0.49%
Negative asset growth while 4997.T invests at 0.53%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
3.76%
BV/share growth above 1.5x 4997.T's 1.23%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-8.16%
We’re deleveraging while 4997.T stands at 9.37%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
7.59%
R&D growth of 7.59% while 4997.T is zero. Bruce Berkowitz checks if the moderate investment leads to meaningful product differentiation.
-1.72%
We cut SG&A while 4997.T invests at 0.00%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.